CD19-targeted allogeneic CAR T cells

CD19-targeted allogeneic CAR T cells · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19-targeted allogeneic CAR T cells, covering 2026-03-04 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases [Phase 1]

See pricing